- Home
- PSNL vs RCEL Comparison
PSNL vs RCEL Comparison
Compare PSNL & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- RCEL
- Stock Information
- Founded
- PSNL 2011
- RCEL 2020
- Country
- PSNL United States
- RCEL United States
- Employees
- PSNL N/A
- RCEL N/A
- Industry
- PSNL Medical Specialities
- RCEL Medical/Dental Instruments
- Sector
- PSNL Health Care
- RCEL Health Care
- Exchange
- PSNL Nasdaq
- RCEL Nasdaq
- Market Cap
- PSNL 321.1M
- RCEL 310.6M
- IPO Year
- PSNL 2019
- RCEL N/A
- Fundamental
- Price
- PSNL $3.89
- RCEL $11.95
- Analyst Decision
- PSNL Strong Buy
- RCEL Hold
- Analyst Count
- PSNL 4
- RCEL 3
- Target Price
- PSNL $6.81
- RCEL $16.50
- AVG Volume (30 Days)
- PSNL 845.3K
- RCEL 99.4K
- Earning Date
- PSNL 11-06-2024
- RCEL 11-07-2024
- Dividend Yield
- PSNL N/A
- RCEL N/A
- EPS Growth
- PSNL N/A
- RCEL N/A
- EPS
- PSNL N/A
- RCEL N/A
- Revenue
- PSNL $87,489,000.00
- RCEL $60,040,000.00
- Revenue This Year
- PSNL $14.85
- RCEL $34.73
- Revenue Next Year
- PSNL $4.19
- RCEL $54.61
- P/E Ratio
- PSNL N/A
- RCEL N/A
- Revenue Growth
- PSNL 24.05
- RCEL 32.24
- 52 Week Low
- PSNL $1.02
- RCEL $7.51
- 52 Week High
- PSNL $7.20
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- PSNL 37.60
- RCEL 57.86
- Support Level
- PSNL $4.15
- RCEL $11.16
- Resistance Level
- PSNL $5.40
- RCEL $13.37
- Average True Range (ATR)
- PSNL 0.50
- RCEL 0.72
- MACD
- PSNL -0.10
- RCEL 0.12
- Stochastic Oscillator
- PSNL 3.02
- RCEL 57.23
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.